BX-001N Experimental group 2

Phase 2

BX-001N Experimental group 2 is one of 23 therapeutic programs targeting Ischemia Reperfusion Injury. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Ischemia Reperfusion InjuryRecruiting

Ischemia Reperfusion InjuryPhase 2

Recruiting

Competition

Competitive Landscape

31 competitors in Ischemia Reperfusion Injury

#DrugCompanyPhaseTrials

Colcrys

Alnylam Pharmaceuticals

Farxiga

Levitra

Neoral

Remodulin

Nitrostat

VViatris Specialty LLC

Glucophage

Inomax

Cardizem

BBausch Health Americas, Inc.

Approved

—10

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Ischemia Reperfusion Injury

NCT07164833

Clinical

Trials by Indication[1]

Ischemia Reperfusion Injury1 trial

Randomized, Single-blind, Multi-center, Placebo-controlled, Phase 2a Clinical Trial of BX-001N to Prevent From Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE)

Recruiting·BBilix Co.,Ltd.·Phase 2·NCT07164833·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BX-001N Experimental group 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for BX-001N Experimental group 2. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Bilix Co.,Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: BBilix Co.,Ltd.

BX-001N Experimental group 2

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Ischemia Reperfusion Injury1 trial

References

Drug Info

Quick Facts

Related News